The mononucleotide-dependent, nonantisense mechanism of action of phosphodiester and phosphorothioate oligonucleotides depends upon the activity of an ecto-5′-nucleotidase

Blood

Volumn 98, Issue 4, 2001, Pages 995-1002

  Koziolkiewicz, Maria ^a,b,c   Gendaszewska, Edyla ^a,b   Maszewska, Maria ^a,b   Stein, C A ^a,b   Stec, Wojciech J ^a,b  

^a POLISH ACADEMY OF SCIENCES   (Poland)

^b College of Physicians and Surgeons ^*  (United States)

^c CENTRE OF MOLECULAR AND MACROMOLECULAR STUDIES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DEOXYRIBONUCLEOTIDE; ECTO 5' NUCLEOTIDASE; NUCLEOTIDE DERIVATIVE; OLIGONUCLEOTIDE; PHOSPHODIESTER OLIGONUCLEOTIDE; PHOSPHOROTHIOATE OLIGONUCLEOTIDE; RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CATABOLISM; CELL PROLIFERATION; CELL STRAIN HL 60; CELL STRAIN K 562; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME DEGRADATION; HELA CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL;

EID: 0035883088     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.4.995     Document Type: Article

References (45)

1. Wickstrom E. Oligodeoxynucleotide stability in subcellular extracts and culture media. J Biochem Biophys Methods. 1986;13:97-102.
2. Koziolkiewicz M, Wójcik M, Kobylanska A, et al. Stability of stereoregular oligo(nucleoside phosphorothioate)s in human plasma: diastereoselectivity of plasma 3′-exonuclease. Antisense Nucleic Acid Drug Dev. 1997;7:43-48.
3. Gilar M, Belenky A, Budman Y, Smisek DL, Cohen A. Impact of 3′-exonuclease stereoselectivity on the kinetics of phosphorothioate oligonucleotide metabolism. Antisense Nucleic Acids Drug Dev. 1998;8:35-41.
4. Vaerman JL, Moureau P, Deldime F, et al. Antisense oligodeoxyribonucleotides suppress hematologic cell growth through stepwise release of deoxyribonucleotides. Blood. 1997;90:331-339.
5. Theiss JC, Morris NR, Fischer GA. Pyrimidine nucleotide metabolism in L5178Y murine leukemia cells: deoxycytidine protection from deoxyguanosine toxicity. Cancer Biochem Biophys. 1976;1:211-214.
6. Fox RM, Tripp EH, Tattersall MHN. Mechanism of deoxycytidine rescue of thymidine toxicity in human T-leukemic lymphocytes. Cancer Res. 1980;40:1718-1721.
7. Ross DD, Akman SA, Schrecker AW, Bachur NR. Effects of deoxynucleosides on cultured human leukemia cell growth and deoxynucleotide pools. Cancer Res. 1981;41:4493-4498.
8. Spaapen LJ, Rijkers GT, Staal GE, et al. The effect of deoxyguanosine on human lymphocyte function, I: analysis of the interference with lymphocyte proliferation in vitro. J Immunol. 1984;132:2311-2317.
9. Stec WJ, Grajkowski A, Kobylanska A, et al. Diastereomers of 3′-O-(2-thio-1.3.2-oxathia-(selena)phospholanes): building blocks for stereocontrolled synthesis of oligo(nucleoside phosphorothioate)s. J Am Chem Soc. 1995;117:12019-12028.
10. Stec WJ, Cierniewski CS, Okruszek A, et al. Stereodependent inhibition of plasminogen activator inhibitor type 1 by phosphorothioate oligonucleotides: proof of sequence specificity in cell culture and in vivo rat experiments. Antisense Nucleic Acid Drug Dev. 1997;7:567-573.
11. Buczko W, Cierniewski CS, Kobylanska A, et al. Modulation of PAI-1 biosynthesis in vitro and in vivo with oligo(nucleoside phosphorothioate)s and related constructs. Pharmacol Ther. 1997;76:161-175.
12. 2-purinergic receptors for extracellular ATP and other nucleotides. Am J Physiol. 1993;265: C577-C606.
13. Murray AW, Atkinson MR. Adenosine 5′-phosphorothioate: a nucleotide analog that is a substrate, competitive inhibitor or regulator of some enzymes that interact with adenosine 5′-phosphate. Biochemistry. 1968;7:4023-4029.
14. Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods. 1989;119:203-210.
15. Zimmermann H. 5′-nucleotidase: molecular structure and functional aspects. Biochem J. 1992;285:345-365.
16. Scharenberg JG, Spaapen LJ, Rijkers GT, et al. Functional and mechanistic studies on the toxicity of deoxyguanosine for the in vitro proliferation and differentiation of human peripheral blood B lymphocytes. Eur J Immunol. 1986;16:381-387.
17. Dahbo Y, Eriksson S. On the mechanism of deoxyribonucleoside toxicity in human T-lymphoblastoid cells: reversal of growth inhibition by addition of cytidine. Eur J Biochem. 1985;150:429-434.
18. Sidi Y, Mitchell BS. 2′-Deoxyguanosine toxicity for B and mature T lymphoid cell lines is mediated by guanine ribonucleotide accumulation. J Clin Invest. 1984;74:1640-1648.
19. Pastor-Anglada M, Felipe A, Casado FJ. Transport and mode of action of nucleoside derivatives used in chemical and antiviral therapies. Trends Pharmacol Sci. 1998;19:424-430.
20. Cusack NJ, Pearson JD, Gordon JL. Stereoselectivity of ectonucleotidases on vascular endothelial cells. Biochem J. 1983;214:975-981.
21. Pearson JD, Coade SB, Cusack NJ. Characterization of ectonucleotidases on vascular smooth muscle cells. Biochem J. 1985;230:503-507.
22. Naito Y, Lowenstein JM. 5′-Nucleotidase from rat heart membranes: inhibition by adenine nucleotides and related compounds. Biochem J. 1985;226:645-651.
23. Williams M, Jarvis MF. Purinergic and pyrimidinergic receptors as potential drug targets. Biochem Pharmacol. 2000;59;1173-1185.
24. Michel AD, Chau NM, Fan TP, Frost EE, Humphrey PP. Evidence that [3H]-alpha,beta-methylene ATP may label endothelial-derived cell line 5′-nucleotidase with high affinity. Br J Pharmacol. 1995;115:767-774.
25. Ziganshin AU, Ziganshina LE, Bodin P, Bailey D, Burnstock G. Effects of P2-purinoceptor antagonists on ecto-nucleotidase activity of guinea-pig vas deferens cultured smooth muscle cells. Biochem Mol Biol Int. 1995;36:863-869.
26. Spychala J, Mitchell BS, Barankiewicz J. Adenosine metabolism during phorbol myristate acetate-mediated induction of HL-60 cell differentiation. J Immunol. 1997;158:4947-4952.
27. Clifford EE, Martin KA, Dalal P, Thomas R, Dubyak GR. Stage-specific expression of P2Y receptors, ecto-apyrase, and ecto-5′-nucleotidase in myeloid leukocytes. Am J Physiol. 1997;273:C973-C987.
28. Kara J, Duschinsky R. Inhibition of thymidylate kinase and DNA synthesis in HeLa cells by 5′-deoxythymidine. Biochim Biophys Acta. 1969;186:223-225.
29. Chae CB, Dobbis MC, Irvin JL, Piantadosi C. Inhibition of thymidylate acid kinase by 5′-substituted pyrimidines. Biochem Pharmacol. 1972;21:761-770.
30. Jin J, Dasarl VR, Sistare FD, Kunapuli SP. Distribution of P2Y receptor subtypes on haematopoietic cells. Br J Pharmacol. 1998;123:789-794.
31. Boyer JL, Delaney SM, Villanueva D, Harden TK. A molecularly identified P2Y receptor simultaneously activates phospholipase and inhibits adenylyl cyclase and is nonselectively activated by all nucleoside triphosphates. Mol Pharmacol. 2000;57:805-810.
32. Pavenstadt H, Spath M, Schlunck G, et al. Effect of nucleotides on the cytosolic free calcium activity and inositol phosphate formation in human glomerular epithelial cells. Br J Pharmacol. 1992;107:189-195.
33. 2 cells by nucleosides and nucleotides: the role of ectoenzymes. Biochem J. 1996;316:551-557.
34. Conant AR, Fisher MJ, McLennan AG, Simpson AWM. Characterization of the P2 receptors on the human umbilical vein endothelial cell line ECV304. Br J Pharmacol. 1998;125:357-364.
35. Conigrave AD, Lee JY, van der Weyden L, et al. Pharmacological profile of a novel cyclic AMP-linked P2 receptor on undifferentiated HL-60 leukemia cells. Br J Pharmacol. 1998;124:1580-1585.
36. Communi D, Robaye B, Boeynaems JM. Pharmacological characterization of the human P2Y11 receptor. Br J Pharmacol. 1999;128:1199-1206.
37. Lazarowski ER, Homolya L, Boucher RC, Harden TK. Identification of an ecto-nucleoside diphosphokinase and its contribution to interconversion of P2 receptor agonists. J Biol Chem. 1997;272:20402-20407.
38. Stein CA. Phosphorothioate antisense oligodeoxynucleotides: questions of specificity. Trends Biotechnol. 1996;14:147-149.
39. Agrawal S, Zhao Q. Antisense therapeutics. Curr Opin Chem Biol. 1998;2:519-528.
40. Rando RF, Hogan ME. Biological activity of guanosine quartet-forming oligonucleotides. In: Stein CA, Krieg AM, eds. Applied Antisense Oligonucleotide Technology. New York, NY: Wiley-Liss;1998:335-352.
41. Krieg AM. Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta. 1999;1489:107-116.
42. Barton CM, Lemoine NR. Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression. Br J Cancer. 1995;71:429-437.
43. Smetsers TFCM, Linders EHP, van de Locht LTF, de Witte TM, Mensink EJBM. An antisense Bcr-Abl phosphodiester-tailed methylphosphonate oligonucleotide reduces the growth of chronic myeloid leukaemia patient cells by a non-antisense mechanism. Br J Haematol. 1997;96:377-381.
44. 3H-labeled oligonucleotides, I: comparison of a phosphodiester and a phosphorothioate. Mol Pharmacol. 1994;45:932-943.
45. Temsamani J, Roskey A, Chaix C, Agrawal S. In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotide. Antisense Nucleic Acid Drug Dev. 1997;7:159-165.